SLC5A2 and type 2 diabetes mellitus: In recent years we have experienced a revolution in the treatment of type 2 diabetes mellitus (T2D), with the approval of new drugs such as sodium-glucose cotransporter 2 (SGLT2) inhibitors, which are effective in improving glycemic control and offer protection against cardiovascular and renal outcomes [1,2], which is why they are being frequently paired with the first-line therapy for T2D, metformin.